Bernd Seizinger
Director/Board Member at APTOSE BIOSCIENCES INC.
Net worth: 2 M $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| William Rice | M | 65 | 11 years | |
| Thomas Meier | M | 62 | 20 years | |
| Leonard Kruimer | M | 66 | 8 years | |
| Scott Rocklage | M | 69 |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 8 years |
| Matthew Coffey | M | - | 13 years | |
| Björn Frendéus | M | 51 | 23 years | |
| Agnete Brunsvik Fredriksen | M | 47 | 17 years | |
| Martin Welschof | M | 63 | 6 years | |
| Christian Rohlff | M | 62 |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | 21 years |
| Richard Peters | M | 61 | 4 years | |
| Oren Gilad | M | 56 | 2 years | |
| John Henneman | M | 62 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 5 years |
| John Hamill | M | 60 | 1 years | |
| Wayne Pisano | M | 69 | 11 years | |
| Jean Bizzari | M | 69 |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | 1 years |
| Lars Wegner | M | 50 |
Turbine Simulated Cell Technologies Ltd.
 Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | 1 years |
| Anne Michelle Whitaker | F | 56 | - | |
| Jeremy Skillington | M | 53 |
TriMod Therapeutics Ltd.
 TriMod Therapeutics Ltd. BiotechnologyHealth Technology TriMod Therapeutics Ltd develops novel platform technologies to treat cancer and autoimmune diseases. It offers TriMoVac technology that enhances the patients' immune response to the tumour and promotes its eradication by attenuating its' immune subversion strategies. The company was founded by Kingston Mills and Jeremy Skillingtonand in 2011 is headquartered in Dublin, Ireland. | 13 years |
| Deborah Brown | F | - | 7 years | |
| Jane Rhodes | M | 56 |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | 1 years |
| Kirk Look | M | - | 21 years | |
| Szabolcs Nagy | M | 35 |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | - |
| Oliver Strub | M | 61 | 18 years | |
| Marc Duey | M | 68 | 2 years | |
| Michael Grissinger | M | 68 | 2 years | |
| Kristoffer Bissessar | M | 56 | 6 years | |
| Kristof Zsolt Szalay | M | 38 |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | - |
| Anna Martling | M | 55 |
Karolinska Institutet
| - |
| Gabriela Gruia | M | 67 | 1 years | |
| Milind Kamkolkar | M | - |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | 1 years |
| Thomas Perlmann | M | - |
Karolinska Institutet
| - |
| Susan Pietropaolo | F | - | - | |
| Rakesh Kumar Jain | M | 74 |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA.
Harvard Medical School
| 33 years |
| Carol Ashe | F | 66 | 6 years | |
| Stefan Ericsson | M | 61 | 26 years | |
| Cecilia Hofvander | F | - | 3 years | |
| Mark Vincent | M | 71 | 17 years | |
| Angela Holtham | F | 73 | 10 years | |
| Vincent Ossipow | M | 55 | 8 years | |
| Rifat Pamukcu | M | 66 | 2 years | |
| Daniel Veres | M | 35 |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | - |
| Warren Whitehead | M | 71 | 13 years | |
| Hans Lennart Rudolf Wigzell | M | 86 |
Karolinska Institutet
| 29 years |
| Klas Kärre | M | 70 |
Karolinska Institutet
| - |
| Peter Sjöstrand | M | 78 |
Karolinska Institutet
| - |
| Denis Burger | M | 80 | 17 years | |
| Michael Engsig | M | - | 17 years | |
| Erich Maximilian Platzer | M | 74 | 10 years | |
| Olle Kämpe | M | 68 |
Karolinska Institutet
| - |
| Ronald Li | M | - |
Karolinska Institutet
| 8 years |
| Joakim Tedroff | M | 63 |
Karolinska Institutet
| - |
| Daniela Tsoneva | F | - |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | 2 years |
| George Church | M | 69 |
Harvard Medical School
| 38 years |
| Peter Sackey | M | 53 |
Karolinska Institutet
| - |
| Anders Vahlne | M | 78 |
Karolinska Institutet
| 30 years |
| Knut Martin Henschen Ingvar | M | 69 |
Karolinska Institutet
| - |
| Elias Arnér | M | - |
Karolinska Institutet
| - |
| Martin Schalling | M | - |
Karolinska Institutet
| - |
| Caroline Ingre | M | 47 |
Karolinska Institutet
| - |
| Einar Jørgen Greve | M | 64 | - | |
| Peter Fatum | M | - | 3 years | |
| Brooks Ensign | M | - | - | |
| Mette Husbyn | M | - | 7 years | |
| Magnus Westgren | M | 73 |
Karolinska Institutet
| 18 years |
| Anvesh Ramineni | M | - |
Turbine Simulated Cell Technologies Ltd.
Turbine Simulated Cell Technologies Ltd. Information Technology ServicesTechnology Services Turbine Simulated Cell Technologies Ltd. is a British company that leverages AI technology to understand oncology patients with simulated cells. The company is based in London, UK. and has subsidiaries in Hungary. The company was founded in 2019 by Szabolcs Nagy, Ivan Fekete, Daniel Veres, Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2019. | 1 years |
| Harald Gurvin | M | 49 | 3 years | |
| Ola Winqvist | M | 58 |
Karolinska Institutet
| - |
| Torgny H. Svensson | M | - |
Karolinska Institutet
| - |
| Erik Gustav Magnus Axelson | M | - |
Karolinska Institutet
| - |
| Lars Olov Larsson | M | - |
Karolinska Institutet
| - |
| Gunvor Ester Ekman-Ordeberg | M | 80 |
Karolinska Institutet
| 23 years |
| Lennart Hammarstrom | M | - |
Karolinska Institutet
| - |
| Kenneth R. Chien | M | - |
Karolinska Institutet
| - |
| John Arne Øvretveit | M | - |
Karolinska Institutet
| - |
| Rolf Valter Rikard Kiessling | M | 76 |
Karolinska Institutet
| 30 years |
| Ralf Morgenstern | M | 72 |
Karolinska Institutet
| - |
| Elaine Sullivan | M | 63 | 2 years | |
| Carl Johan Bertil Sundberg | M | 66 |
Karolinska Institutet
| - |
| George Demetri | M | 67 |
Harvard Medical School
| 36 years |
| Alf Gunnar Martin Nicklasson | M | 69 | 3 years | |
| Rolf Lewensohn | M | - |
Karolinska Institutet
| - |
| Birgitte Volck | M | 61 | 3 years | |
| Per Axel Tomas Södersten | M | 79 |
Karolinska Institutet
| - |
| Per Magnus Gerde | M | - |
Karolinska Institutet
| - |
| Kerstin Uvnäs Moberg | M | 80 |
Karolinska Institutet
| - |
| Jason Gould | M | 55 |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | - |
| David H. Sachs | M | 77 |
Harvard Medical School
| 33 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christian Schade | M | 63 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 7 years |
| Bradley Thompson | M | 67 | 17 years | |
| Francesco Sinigaglia | M | 71 |
BioXell SpA
 BioXell SpA BiotechnologyHealth Technology BioXell SpA provides medical services. The company researches and develops drugs to treat urological, inflammatory, and related disorders. The company was founded in 2002 and is headquartered in Segrate, Italy. | 10 years |
| Johan Rutger Christenson | M | 65 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | - |
| Barbara Anna Heller | F | 56 | 7 years | |
| Jonathan Hepple | M | 53 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 5 years |
| Martin Gertsch | M | 59 | 15 years | |
| Guido Magni | M | 70 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 4 years |
| Scott Coiante | M | 57 |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | 4 years |
| Michael Oredsson | M | 64 | 5 years | |
| Charles Homcy | M | 75 |
The General Hospital Corp.
The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA.
Harvard Medical School
| 11 years |
| Lars Ingelmark | M | 75 | 12 years | |
| Anna Moore | M | - |
The General Hospital Corp.
The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA.
Harvard Medical School
| 26 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Sweden | 46 | 46.00% |
| United States | 21 | 21.00% |
| Canada | 15 | 15.00% |
| United Kingdom | 11 | 11.00% |
| Norway | 10 | 10.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bernd Seizinger
- Personal Network
